Fractyl Health, Inc. (NASDAQ:GUTS) Insider Sells $40,446.26 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 22,346 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $1.81, for a total value of $40,446.26. Following the completion of the transaction, the insider now owns 153,544 shares in the company, valued at $277,914.64. The trade was a 12.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jay David Caplan also recently made the following trade(s):

• On Monday, November 11th, Jay David Caplan sold 64,197 shares of Fractyl Health stock. The shares were sold at an average price of $2.47, for a total transaction of $158,566.59.

Fractyl Health Price Performance

Fractyl Health stock opened at $1.64 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. Fractyl Health, Inc. has a 52 week low of $1.52 and a 52 week high of $11.55. The stock has a market capitalization of $78.88 million and a P/E ratio of -0.13. The stock has a fifty day moving average of $2.03 and a 200-day moving average of $2.47.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The company had revenue of $0.01 million during the quarter. On average, sell-side analysts expect that Fractyl Health, Inc. will post -1.66 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley cut their price target on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a report on Monday.

Hedge Funds Weigh In On Fractyl Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its stake in shares of Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock worth $53,000 after buying an additional 7,397 shares during the last quarter. Bank of New York Mellon Corp grew its position in Fractyl Health by 27.3% during the 4th quarter. Bank of New York Mellon Corp now owns 41,448 shares of the company’s stock worth $85,000 after acquiring an additional 8,886 shares during the last quarter. Jane Street Group LLC acquired a new position in Fractyl Health in the 3rd quarter worth about $25,000. Rhumbline Advisers raised its position in Fractyl Health by 73.1% in the fourth quarter. Rhumbline Advisers now owns 25,626 shares of the company’s stock valued at $53,000 after purchasing an additional 10,826 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Fractyl Health by 335.4% during the third quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock valued at $37,000 after purchasing an additional 11,406 shares in the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.